Top Markets
#1 Ontology Gas Ontology Gas +23.38%
#2 EXOD EXOD +22.08%
#3 Status Status +20.38%
#4 ETHGas ETHGas +14.18%
#5 aelf aelf +13.27%
#6 Fake World Assets Fake World Assets +10.63%
#7 The Black Bull The Black Bull +10.03%
#8 Derive Derive +8.64%
#9 Gas Gas +7.44%
#10 Meteora Meteora +6.38%
Coin of the day
Ontology Gas Ontology Gas
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Clasificación en acciones #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Precio por acción
$9.81
Última sincronización: 2025-03-18
Capitalización bursátil
$48.68M
Cambio (1 día)
1.55%
Cambio (1 año)
0.00%
País
US
Comercio AlloVir, Inc. (ALVR)

Categoría

Healthcare
Ganancias de AlloVir, Inc. (ALVR)
Ganancias en Jun 2026 TTM: $-54.46M
Secondo gli ultimi rapporti finanziari di AlloVir, Inc., gli utili attuali della società sono $-54.46M. Nel 2023, la società ha registrato un utile di $-190.54M, una disminución en comparación con agli utili del 2022, che erano di $-168.98M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de AlloVir, Inc. desde 2018 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-54.46M -7.33%
2024 $-58.77M -69.16%
2023 $-190.54M 12.76%
2022 $-168.98M -1.16%
2021 $-170.96M 144.98%
2020 $-69.78M 192.73%
2019 $-23.84M 881.03%
2018 $-2.43M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -9,786.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,681.87%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -3,064.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 5,568.48%
US